ResearcherDepartment of Cancer Studies, University of Leicester, Leicester Royal Infirmary, Leicester LE2 7LXNo recent work listed

Dean Fennell

Provisional: name at one institution (moderate confidence, 0.60), identity_conf@1As of 8 November 2026

Known by name at one institution; no external author ID yet. Sources: ClinicalTrials.gov.

Their work

Papers: 0
Trials: 1 (principal investigator on 1)
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2017: 1 trial

Trials 1

Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) Principal investigator NCT02758587 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Stefan Nicholas Symeonides · 1 shared trial, 2017 · strength 0.13
- Trial Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) NCT02758587 ↗
Christian Ottensmeier · 1 shared trial, 2017 · strength 0.13
- Trial Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) NCT02758587 ↗
Jeff Evans · 1 shared trial, 2017 · strength 0.13
- Trial Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) NCT02758587 ↗
Vicky Coyle · 1 shared trial, 2017 · strength 0.13
- Trial Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) NCT02758587 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.